ADR,SEQ,PT,HLT,HLGT,SOC_ABBREV,FATAL_YN
1,1,Hypercalcaemia,Calcium metabolism disorders,"Bone, calcium, magnesium and phosphorus metabolism disorders",Metab,N
2,1,Diarrhoea,Diarrhoea (excl infective),Gastrointestinal motility and defaecation conditions,Gastr,N
3,1,Abdominal pain,Gastrointestinal and abdominal pains (excl oral and throat),Gastrointestinal signs and symptoms,Gastr,N
3,2,Diarrhoea,Diarrhoea (excl infective),Gastrointestinal motility and defaecation conditions,Gastr,N
4,1,Hypertriglyceridaemia,Elevated triglycerides,Lipid metabolism disorders,Metab,N
5,1,Influenza like illness,General signs and symptoms NEC,General system disorders NEC,Genrl,N
5,2,Pain,Pain and discomfort NEC,General system disorders NEC,Genrl,N
6,1,Alopecia,Alopecias,Skin appendage conditions,Skin,N
7,1,Arthralgia,Joint related signs and symptoms,Joint disorders,Musc,N
7,2,Pyrexia,Febrile disorders,Body temperature conditions,Genrl,N
8,1,Chest pain,Pain and discomfort NEC,General system disorders NEC,Genrl,N
9,1,Dyspnoea,Breathing abnormalities,Respiratory disorders NEC,Resp,N
10,1,Visual acuity reduced,Visual impairment and blindness (excl colour blindness),Vision disorders,Eye,N
11,1,Back pain,Musculoskeletal and connective tissue pain and discomfort,Musculoskeletal and connective tissue disorders NEC,Musc,N
12,1,Circulatory collapse,Circulatory collapse and shock,Decreased and nonspecific blood pressure disorders and shock,Vasc,N
12,2,Dizziness,Neurological signs and symptoms NEC,Neurological disorders NEC,Nerv,N
12,3,Headache,Headaches NEC,Headaches,Nerv,N
12,4,Loss of consciousness,Disturbances in consciousness NEC,Neurological disorders NEC,Nerv,N
13,1,Full blood count decreased,Blood counts NEC,Haematology investigations (incl blood groups),Inv,N
14,1,Arthralgia,Joint related signs and symptoms,Joint disorders,Musc,N
14,2,Back pain,Musculoskeletal and connective tissue pain and discomfort,Musculoskeletal and connective tissue disorders NEC,Musc,N
14,3,Blood creatinine increased,Renal function analyses,Renal and urinary tract investigations and urinalyses,Inv,N
14,4,Diarrhoea,Diarrhoea (excl infective),Gastrointestinal motility and defaecation conditions,Gastr,N
14,5,Headache,Headaches NEC,Headaches,Nerv,N
14,6,Myalgia,Muscle pains,Muscle disorders,Musc,N
14,7,Oral herpes,Herpes viral infections,Viral infectious disorders,Infec,N
14,8,Pyrexia,Febrile disorders,Body temperature conditions,Genrl,N
14,9,Renal tubular dysfunction,Nephropathies and tubular disorders NEC,Nephropathies,Renal,N
14,10,Thrombocytopenia,Thrombocytopenias,Platelet disorders,Blood,N
15,1,Injection site reaction,Injection site reactions,Administration site reactions,Genrl,N
15,2,Nausea,Nausea and vomiting symptoms,Gastrointestinal signs and symptoms,Gastr,N
15,3,Pruritus,Pruritus NEC,Epidermal and dermal conditions,Skin,N
16,1,Contusion,Skin injuries NEC,Injuries NEC,Inj&P,N
17,1,Deep vein thrombosis,Peripheral embolism and thrombosis,Embolism and thrombosis,Vasc,N
17,2,Dyspnoea,Breathing abnormalities,Respiratory disorders NEC,Resp,N
17,3,Headache,Headaches NEC,Headaches,Nerv,N
17,4,Injection site pain,Injection site reactions,Administration site reactions,Genrl,N
17,5,Musculoskeletal pain,Musculoskeletal and connective tissue pain and discomfort,Musculoskeletal and connective tissue disorders NEC,Musc,N
17,6,Nausea,Nausea and vomiting symptoms,Gastrointestinal signs and symptoms,Gastr,N
17,7,Restlessness,Increased physical activity levels,Changes in physical activity,Psych,N
18,1,Optic nerve injury,Cranial nerve injuries,Injuries NEC,Inj&P,N
18,2,Vitreous detachment,"Choroid and vitreous structural change, deposit and degeneration","Ocular structural change, deposit and degeneration NEC",Eye,N
19,1,Vulvovaginal dryness,Vulvovaginal signs and symptoms,Vulvovaginal disorders (excl infections and inflammations),Repro,N
20,1,Death,Death and sudden death,Fatal outcomes,Genrl,Y
21,1,Death,Death and sudden death,Fatal outcomes,Genrl,Y
22,1,Disease progression,General signs and symptoms NEC,General system disorders NEC,Genrl,N
23,1,Alopecia,Alopecias,Skin appendage conditions,Skin,N
23,2,Arthralgia,Joint related signs and symptoms,Joint disorders,Musc,N
23,3,Epistaxis,Nasal disorders NEC,Upper respiratory tract disorders (excl infections),Resp,N
23,4,Injection site irritation,Injection site reactions,Administration site reactions,Genrl,N
23,5,Joint swelling,Joint related signs and symptoms,Joint disorders,Musc,N
24,1,Fatigue,Asthenic conditions,General system disorders NEC,Genrl,N
24,2,Headache,Headaches NEC,Headaches,Nerv,N
25,1,Cough,Coughing and associated symptoms,Respiratory disorders NEC,Resp,N
25,2,Dizziness,Neurological signs and symptoms NEC,Neurological disorders NEC,Nerv,N
25,3,Gingival pain,"Gingival disorders, signs and symptoms NEC",Dental and gingival conditions,Gastr,N
25,4,Paraesthesia,Paraesthesias and dysaesthesias,Neurological disorders NEC,Nerv,N
25,5,Skin burning sensation,Dermal and epidermal conditions NEC,Epidermal and dermal conditions,Skin,N
25,6,Sneezing,Upper respiratory tract signs and symptoms,Respiratory tract signs and symptoms,Resp,N
26,1,Hypersensitivity,Allergic conditions NEC,Allergic conditions,Immun,N
26,2,Peroneal nerve palsy,Mononeuropathies,Peripheral neuropathies,Nerv,N
27,1,Death,Death and sudden death,Fatal outcomes,Genrl,Y
28,1,Death,Death and sudden death,Fatal outcomes,Genrl,Y
29,1,Death,Death and sudden death,Fatal outcomes,Genrl,Y
30,1,Contusion,Skin injuries NEC,Injuries NEC,Inj&P,N
30,2,Erythema,Erythemas,Epidermal and dermal conditions,Skin,N
30,3,Injection site pain,Injection site reactions,Administration site reactions,Genrl,N
30,4,Swelling,General signs and symptoms NEC,General system disorders NEC,Genrl,N
31,1,Blood creatinine abnormal,Renal function analyses,Renal and urinary tract investigations and urinalyses,Inv,N
31,2,Diarrhoea,Diarrhoea (excl infective),Gastrointestinal motility and defaecation conditions,Gastr,N
31,3,Hypoaesthesia,Paraesthesias and dysaesthesias,Neurological disorders NEC,Nerv,N
31,4,Injection site pruritus,Injection site reactions,Administration site reactions,Genrl,N
31,5,Muscle spasms,Muscle related signs and symptoms NEC,Muscle disorders,Musc,N
31,6,Pain in extremity,Musculoskeletal and connective tissue pain and discomfort,Musculoskeletal and connective tissue disorders NEC,Musc,N
31,7,Pallor,Site specific vascular disorders NEC,Vascular disorders NEC,Vasc,N
31,8,Rash pruritic,"Rashes, eruptions and exanthems NEC",Epidermal and dermal conditions,Skin,N
31,9,Second primary malignancy,Neoplasms malignant site unspecified NEC,Miscellaneous and site unspecified neoplasms malignant and unspecified,Neopl,N
31,10,Vulvovaginal pruritus,Vulvovaginal signs and symptoms,Vulvovaginal disorders (excl infections and inflammations),Repro,N
32,1,Headache,Headaches NEC,Headaches,Nerv,N
32,2,Metastases to bone,Metastases to specified sites,Metastases,Neopl,N
33,1,Hyperkalaemia,Potassium imbalance,Electrolyte and fluid balance conditions,Metab,N
34,1,Deep vein thrombosis,Peripheral embolism and thrombosis,Embolism and thrombosis,Vasc,N
35,1,Blood bilirubin increased,Hepatobiliary function diagnostic procedures,Hepatobiliary investigations,Inv,N
35,2,Metastases to liver,Metastases to specified sites,Metastases,Neopl,N
36,1,Oesophagitis,Oesophagitis (excl infective),Gastrointestinal inflammatory conditions,Gastr,N
37,1,Anaphylactoid reaction,Anaphylactic and anaphylactoid responses,Allergic conditions,Immun,N
38,1,Acute hepatic failure,Hepatic failure and associated disorders,Hepatic and hepatobiliary disorders,Hepat,Y
38,2,Hepatic steatosis,Hepatocellular damage and hepatitis NEC,Hepatic and hepatobiliary disorders,Hepat,N
38,3,Hypertensive heart disease,Cardiac hypertensive complications,"Cardiac disorders, signs and symptoms NEC",Card,N
39,1,Sciatica,Lumbar spinal cord and nerve root disorders,Spinal cord and nerve root disorders,Nerv,N
40,1,Asthenia,Asthenic conditions,General system disorders NEC,Genrl,N
40,2,Hypoaesthesia,Paraesthesias and dysaesthesias,Neurological disorders NEC,Nerv,N
40,3,Nerve injury,Nerve injuries NEC,Injuries NEC,Inj&P,N
40,4,Peroneal nerve palsy,Mononeuropathies,Peripheral neuropathies,Nerv,N
41,1,Breast cancer,Breast and nipple neoplasms malignant,Breast neoplasms malignant and unspecified (incl nipple),Neopl,N
41,2,Malignant neoplasm progression,Neoplasms malignant site unspecified NEC,Miscellaneous and site unspecified neoplasms malignant and unspecified,Neopl,N
41,3,Metastases to liver,Metastases to specified sites,Metastases,Neopl,N
41,4,Rash,"Rashes, eruptions and exanthems NEC",Epidermal and dermal conditions,Skin,N
42,1,Lung neoplasm,Respiratory tract and pleural neoplasms malignancy unspecified NEC,Respiratory and mediastinal neoplasms malignant and unspecified,Neopl,N
43,1,Rash,"Rashes, eruptions and exanthems NEC",Epidermal and dermal conditions,Skin,N
44,1,Breast cancer metastatic,Breast and nipple neoplasms malignant,Breast neoplasms malignant and unspecified (incl nipple),Neopl,Y
45,1,Malignant neoplasm progression,Neoplasms malignant site unspecified NEC,Miscellaneous and site unspecified neoplasms malignant and unspecified,Neopl,N
46,1,Anger,Emotional and mood disturbances NEC,Mood disorders and disturbances NEC,Psych,N
46,2,Back disorder,Musculoskeletal and connective tissue conditions NEC,Musculoskeletal and connective tissue disorders NEC,Musc,N
46,3,Chills,Feelings and sensations NEC,General system disorders NEC,Genrl,N
46,4,Dizziness,Neurological signs and symptoms NEC,Neurological disorders NEC,Nerv,N
46,5,Fall,Non-site specific injuries NEC,Injuries NEC,Inj&P,N
46,6,Gait inability,Gait disturbances,General system disorders NEC,Genrl,N
46,7,Hypoaesthesia,Paraesthesias and dysaesthesias,Neurological disorders NEC,Nerv,N
46,8,Muscle spasms,Muscle related signs and symptoms NEC,Muscle disorders,Musc,N
46,9,Nasopharyngitis,Upper respiratory tract infections,Infections - pathogen unspecified,Infec,N
46,10,Nerve injury,Nerve injuries NEC,Injuries NEC,Inj&P,N
46,11,Paraesthesia,Paraesthesias and dysaesthesias,Neurological disorders NEC,Nerv,N
46,12,Peripheral coldness,"Peripheral vasoconstriction, necrosis and vascular insufficiency","Arteriosclerosis, stenosis, vascular insufficiency and necrosis",Vasc,N
47,1,Neutropenia,Neutropenias,White blood cell disorders,Blood,N
47,2,Off label use,Off label uses,Off label uses and intentional product misuses/use issues,Inj&P,N
48,1,Injection site hypoaesthesia,Injection site reactions,Administration site reactions,Genrl,N
49,1,Dysphagia,Gastrointestinal signs and symptoms NEC,Gastrointestinal signs and symptoms,Gastr,N
49,2,Small intestinal obstruction,Duodenal and small intestinal stenosis and obstruction,Gastrointestinal stenosis and obstruction,Gastr,Y
50,1,Injection site hypoaesthesia,Injection site reactions,Administration site reactions,Genrl,N
51,1,Dyspnoea,Breathing abnormalities,Respiratory disorders NEC,Resp,N
51,2,Gait disturbance,Gait disturbances,General system disorders NEC,Genrl,N
51,3,Injection site erythema,Injection site reactions,Administration site reactions,Genrl,N
51,4,Injection site mass,Injection site reactions,Administration site reactions,Genrl,N
51,5,Lung disorder,Respiratory tract disorders NEC,Respiratory disorders NEC,Resp,N
51,6,Musculoskeletal disorder,Musculoskeletal and connective tissue conditions NEC,Musculoskeletal and connective tissue disorders NEC,Musc,N
51,7,Neck mass,Soft tissue disorders NEC,Musculoskeletal and connective tissue disorders NEC,Musc,N
51,8,Spinal disorder,Bone disorders NEC,Bone disorders (excl congenital and fractures),Musc,N
52,1,Injection site pain,Injection site reactions,Administration site reactions,Genrl,N
52,2,Syncope,Disturbances in consciousness NEC,Neurological disorders NEC,Nerv,N
53,1,Confusional state,Confusion and disorientation,Deliria (incl confusion),Psych,N
53,2,Fatigue,Asthenic conditions,General system disorders NEC,Genrl,N
53,3,Hyponatraemia,Sodium imbalance,Electrolyte and fluid balance conditions,Metab,N
54,1,Alanine aminotransferase increased,Hepatobiliary function diagnostic procedures,Hepatobiliary investigations,Inv,N
54,2,Aspartate aminotransferase increased,Hepatobiliary function diagnostic procedures,Hepatobiliary investigations,Inv,N
54,3,Blood alkaline phosphatase increased,Tissue enzyme analyses NEC,Enzyme investigations NEC,Inv,N
54,4,Blood bilirubin increased,Hepatobiliary function diagnostic procedures,Hepatobiliary investigations,Inv,N
54,5,Blood creatinine increased,Renal function analyses,Renal and urinary tract investigations and urinalyses,Inv,N
54,6,Blood lactate dehydrogenase increased,Tissue enzyme analyses NEC,Enzyme investigations NEC,Inv,N
54,7,Gamma-glutamyltransferase increased,Hepatobiliary function diagnostic procedures,Hepatobiliary investigations,Inv,N
54,8,Malignant neoplasm progression,Neoplasms malignant site unspecified NEC,Miscellaneous and site unspecified neoplasms malignant and unspecified,Neopl,N
54,9,Ovarian cancer,Ovarian neoplasms malignant (excl germ cell),Reproductive neoplasms female malignant and unspecified,Neopl,N
54,10,Product use in unapproved indication,"Medication errors, product use errors and issues NEC",Medication errors and other product use errors and issues,Inj&P,N
54,11,RET gene mutation,Gene mutations and other alterations NEC,"Chromosomal abnormalities, gene alterations and gene variants",Cong,N
55,1,Hepatic failure,Hepatic failure and associated disorders,Hepatic and hepatobiliary disorders,Hepat,Y
55,2,Neoplasm progression,Neoplasms unspecified malignancy and site unspecified NEC,Miscellaneous and site unspecified neoplasms malignant and unspecified,Neopl,N
56,1,Malignant neoplasm progression,Neoplasms malignant site unspecified NEC,Miscellaneous and site unspecified neoplasms malignant and unspecified,Neopl,N
56,2,Metastases to liver,Metastases to specified sites,Metastases,Neopl,N
56,3,Off label use,Off label uses,Off label uses and intentional product misuses/use issues,Inj&P,N
56,4,Product use issue,"Medication errors, product use errors and issues NEC",Medication errors and other product use errors and issues,Inj&P,N
57,1,Hepatic failure,Hepatic failure and associated disorders,Hepatic and hepatobiliary disorders,Hepat,Y
57,2,Malignant neoplasm progression,Neoplasms malignant site unspecified NEC,Miscellaneous and site unspecified neoplasms malignant and unspecified,Neopl,N
57,3,Metastases to liver,Metastases to specified sites,Metastases,Neopl,N
57,4,Off label use,Off label uses,Off label uses and intentional product misuses/use issues,Inj&P,N
58,1,Alopecia,Alopecias,Skin appendage conditions,Skin,N
58,2,Back pain,Musculoskeletal and connective tissue pain and discomfort,Musculoskeletal and connective tissue disorders NEC,Musc,N
58,3,Injection site bruising,Injection site reactions,Administration site reactions,Genrl,N
58,4,Injection site pain,Injection site reactions,Administration site reactions,Genrl,N
58,5,Injection site scar,Injection site reactions,Administration site reactions,Genrl,N
58,6,Intentional product use issue,Intentional product use issues,Off label uses and intentional product misuses/use issues,Inj&P,N
58,7,Lipoatrophy,Lipodystrophies,Skin and subcutaneous tissue disorders NEC,Skin,N
58,8,Madarosis,Alopecias,Skin appendage conditions,Skin,N
58,9,Metastases to lung,Metastases to specified sites,Metastases,Neopl,N
58,10,Metastases to lymph nodes,Metastases to specified sites,Metastases,Neopl,N
58,11,Off label use,Off label uses,Off label uses and intentional product misuses/use issues,Inj&P,N
58,12,Pain in extremity,Musculoskeletal and connective tissue pain and discomfort,Musculoskeletal and connective tissue disorders NEC,Musc,N
58,13,Sciatica,Lumbar spinal cord and nerve root disorders,Spinal cord and nerve root disorders,Nerv,N
58,14,Skin sensitisation,Dermal and epidermal conditions NEC,Epidermal and dermal conditions,Skin,N
59,1,Amenorrhoea,Menstruation with decreased bleeding,Menstrual cycle and uterine bleeding disorders,Repro,N
59,2,Asthenia,Asthenic conditions,General system disorders NEC,Genrl,N
59,3,Fatigue,Asthenic conditions,General system disorders NEC,Genrl,N
59,4,Gastrointestinal disorder,Gastrointestinal disorders NEC,Gastrointestinal conditions NEC,Gastr,N
59,5,Headache,Headaches NEC,Headaches,Nerv,N
59,6,Hot flush,Peripheral vascular disorders NEC,Vascular disorders NEC,Vasc,N
59,7,Menopausal symptoms,Menopausal effects NEC,Menopause related conditions,Repro,N
59,8,Mood swings,Fluctuating mood symptoms,Mood disorders and disturbances NEC,Psych,N
59,9,Muscular weakness,Muscle weakness conditions,Muscle disorders,Musc,N
59,10,Nausea,Nausea and vomiting symptoms,Gastrointestinal signs and symptoms,Gastr,N
59,11,Neutropenia,Neutropenias,White blood cell disorders,Blood,N
59,12,Taste disorder,Sensory abnormalities NEC,Neurological disorders NEC,Nerv,N
59,13,Urticaria,Urticarias,Angioedema and urticaria,Skin,N
59,14,Vision blurred,Visual disorders NEC,Vision disorders,Eye,N
59,15,Weight decreased,Physical examination procedures and organ system status,Physical examination and organ system status topics,Inv,N
60,1,Fear of injection,Fear symptoms and phobic disorders (incl social phobia),Anxiety disorders and symptoms,Psych,N
60,2,Hypoaesthesia,Paraesthesias and dysaesthesias,Neurological disorders NEC,Nerv,N
60,3,Incorrect route of product administration,Product administration errors and issues,Medication errors and other product use errors and issues,Inj&P,N
61,1,Blood pressure increased,Vascular tests NEC (incl blood pressure),Cardiac and vascular investigations (excl enzyme tests),Inv,N
61,2,Cough,Coughing and associated symptoms,Respiratory disorders NEC,Resp,N
61,3,Dyspnoea,Breathing abnormalities,Respiratory disorders NEC,Resp,N
61,4,Erythema,Erythemas,Epidermal and dermal conditions,Skin,N
62,1,Metastases to bone,Metastases to specified sites,Metastases,Neopl,N
62,2,Neutrophil count decreased,White blood cell analyses,Haematology investigations (incl blood groups),Inv,N
62,3,Platelet count decreased,Platelet analyses,Haematology investigations (incl blood groups),Inv,N
62,4,White blood cell count decreased,White blood cell analyses,Haematology investigations (incl blood groups),Inv,N
63,1,Hepatic failure,Hepatic failure and associated disorders,Hepatic and hepatobiliary disorders,Hepat,N
64,1,Hepatic cirrhosis,Hepatic fibrosis and cirrhosis,Hepatic and hepatobiliary disorders,Hepat,Y
65,1,Malignant neoplasm progression,Neoplasms malignant site unspecified NEC,Miscellaneous and site unspecified neoplasms malignant and unspecified,Neopl,Y
66,1,Amenorrhoea,Menstruation with decreased bleeding,Menstrual cycle and uterine bleeding disorders,Repro,N
66,2,Asthenia,Asthenic conditions,General system disorders NEC,Genrl,N
66,3,Fatigue,Asthenic conditions,General system disorders NEC,Genrl,N
66,4,Gastrointestinal disorder,Gastrointestinal disorders NEC,Gastrointestinal conditions NEC,Gastr,N
66,5,Headache,Headaches NEC,Headaches,Nerv,N
66,6,Hot flush,Peripheral vascular disorders NEC,Vascular disorders NEC,Vasc,N
66,7,Menopausal symptoms,Menopausal effects NEC,Menopause related conditions,Repro,N
66,8,Mood swings,Fluctuating mood symptoms,Mood disorders and disturbances NEC,Psych,N
66,9,Muscular weakness,Muscle weakness conditions,Muscle disorders,Musc,N
66,10,Nausea,Nausea and vomiting symptoms,Gastrointestinal signs and symptoms,Gastr,N
66,11,Neutropenia,Neutropenias,White blood cell disorders,Blood,N
66,12,Off label use,Off label uses,Off label uses and intentional product misuses/use issues,Inj&P,N
66,13,Taste disorder,Sensory abnormalities NEC,Neurological disorders NEC,Nerv,N
66,14,Urticaria,Urticarias,Angioedema and urticaria,Skin,N
66,15,Vision blurred,Visual disorders NEC,Vision disorders,Eye,N
66,16,Weight decreased,Physical examination procedures and organ system status,Physical examination and organ system status topics,Inv,N
67,1,BRAF gene mutation,Gene mutations and other alterations NEC,"Chromosomal abnormalities, gene alterations and gene variants",Cong,N
67,2,Back pain,Musculoskeletal and connective tissue pain and discomfort,Musculoskeletal and connective tissue disorders NEC,Musc,N
67,3,Blood alkaline phosphatase increased,Tissue enzyme analyses NEC,Enzyme investigations NEC,Inv,N
67,4,Bone disorder,Bone disorders NEC,Bone disorders (excl congenital and fractures),Musc,N
67,5,Bone pain,Bone related signs and symptoms,Bone disorders (excl congenital and fractures),Musc,N
67,6,Breast cancer stage IV,Breast and nipple neoplasms malignant,Breast neoplasms malignant and unspecified (incl nipple),Neopl,N
67,7,Malignant neoplasm progression,Neoplasms malignant site unspecified NEC,Miscellaneous and site unspecified neoplasms malignant and unspecified,Neopl,N
67,8,Spinal cord compression,Spinal cord and nerve root disorders NEC,Spinal cord and nerve root disorders,Nerv,N
68,1,Dehydration,Total fluid volume decreased,Electrolyte and fluid balance conditions,Metab,N
68,2,Full blood count decreased,Blood counts NEC,Haematology investigations (incl blood groups),Inv,N
68,3,Malaise,Asthenic conditions,General system disorders NEC,Genrl,N
69,1,Nausea,Nausea and vomiting symptoms,Gastrointestinal signs and symptoms,Gastr,N
69,2,Pain,Pain and discomfort NEC,General system disorders NEC,Genrl,N
69,3,Pancreatitis acute,Acute and chronic pancreatitis,Exocrine pancreas conditions,Gastr,N
70,1,Breast cancer recurrent,Breast and nipple neoplasms malignant,Breast neoplasms malignant and unspecified (incl nipple),Neopl,N
70,2,Horner's syndrome,Autonomic nervous system disorders,Neuromuscular disorders,Nerv,N
70,3,Malignant neoplasm progression,Neoplasms malignant site unspecified NEC,Miscellaneous and site unspecified neoplasms malignant and unspecified,Neopl,N
70,4,Metastases to skin,Metastases to specified sites,Metastases,Neopl,N
71,1,Malignant neoplasm progression,Neoplasms malignant site unspecified NEC,Miscellaneous and site unspecified neoplasms malignant and unspecified,Neopl,Y
72,1,BRAF gene mutation,Gene mutations and other alterations NEC,"Chromosomal abnormalities, gene alterations and gene variants",Cong,N
72,2,Back pain,Musculoskeletal and connective tissue pain and discomfort,Musculoskeletal and connective tissue disorders NEC,Musc,N
72,3,Blood alkaline phosphatase increased,Tissue enzyme analyses NEC,Enzyme investigations NEC,Inv,N
72,4,Bone disorder,Bone disorders NEC,Bone disorders (excl congenital and fractures),Musc,N
72,5,Bone pain,Bone related signs and symptoms,Bone disorders (excl congenital and fractures),Musc,N
72,6,Breast cancer stage IV,Breast and nipple neoplasms malignant,Breast neoplasms malignant and unspecified (incl nipple),Neopl,N
72,7,Malignant neoplasm progression,Neoplasms malignant site unspecified NEC,Miscellaneous and site unspecified neoplasms malignant and unspecified,Neopl,N
72,8,Spinal cord compression,Spinal cord and nerve root disorders NEC,Spinal cord and nerve root disorders,Nerv,N
73,1,Neoplasm progression,Neoplasms unspecified malignancy and site unspecified NEC,Miscellaneous and site unspecified neoplasms malignant and unspecified,Neopl,N
73,2,Neutropenia,Neutropenias,White blood cell disorders,Blood,N
74,1,Flushing,Peripheral vascular disorders NEC,Vascular disorders NEC,Vasc,N
74,2,Pruritus,Pruritus NEC,Epidermal and dermal conditions,Skin,N
74,3,Rash,"Rashes, eruptions and exanthems NEC",Epidermal and dermal conditions,Skin,N
75,1,Bradycardia,Rate and rhythm disorders NEC,Cardiac arrhythmias,Card,N
75,2,Flushing,Peripheral vascular disorders NEC,Vascular disorders NEC,Vasc,N
75,3,Paraesthesia oral,Oral soft tissue signs and symptoms,Oral soft tissue conditions,Gastr,N
76,1,Acute coronary syndrome,Ischaemic coronary artery disorders,Coronary artery disorders,Card,N
76,2,Cardiac failure congestive,Heart failures NEC,Heart failures,Card,N
76,3,Product dose omission issue,Product administration errors and issues,Medication errors and other product use errors and issues,Inj&P,N
76,4,Respiratory disorder,Respiratory tract disorders NEC,Respiratory disorders NEC,Resp,N
77,1,Neoplasm progression,Neoplasms unspecified malignancy and site unspecified NEC,Miscellaneous and site unspecified neoplasms malignant and unspecified,Neopl,N
77,2,Neutropenia,Neutropenias,White blood cell disorders,Blood,N
78,1,Hepatic failure,Hepatic failure and associated disorders,Hepatic and hepatobiliary disorders,Hepat,Y
78,2,Malignant neoplasm progression,Neoplasms malignant site unspecified NEC,Miscellaneous and site unspecified neoplasms malignant and unspecified,Neopl,N
78,3,Metastasis,Metastases to unknown and unspecified sites,Metastases,Neopl,N
78,4,Urinary tract infection,Urinary tract infections,Infections - pathogen unspecified,Infec,N
79,1,Incorrect dose administered,Product administration errors and issues,Medication errors and other product use errors and issues,Inj&P,N
80,1,Acute abdomen,Gastrointestinal signs and symptoms NEC,Gastrointestinal signs and symptoms,Gastr,N
81,1,Haemodynamic instability,Non-site specific vascular disorders NEC,Vascular disorders NEC,Vasc,N
81,2,Hypokalaemia,Potassium imbalance,Electrolyte and fluid balance conditions,Metab,N
81,3,Metabolic acidosis,Metabolic acidoses (excl diabetic acidoses),Acid-base disorders,Metab,N
81,4,Neutropenic sepsis,"Sepsis, bacteraemia, viraemia and fungaemia NEC",Infections - pathogen unspecified,Infec,Y
82,1,Dyspnoea,Breathing abnormalities,Respiratory disorders NEC,Resp,N
83,1,Breast cancer metastatic,Breast and nipple neoplasms malignant,Breast neoplasms malignant and unspecified (incl nipple),Neopl,N
83,2,Malignant neoplasm progression,Neoplasms malignant site unspecified NEC,Miscellaneous and site unspecified neoplasms malignant and unspecified,Neopl,N
83,3,Metastases to spinal cord,Metastases to specified sites,Metastases,Neopl,N
83,4,PIK3CA-activated mutation,Gene mutations and other alterations NEC,"Chromosomal abnormalities, gene alterations and gene variants",Cong,N
83,5,Rash maculo-papular,"Rashes, eruptions and exanthems NEC",Epidermal and dermal conditions,Skin,N
83,6,Vertigo,Inner ear signs and symptoms,Inner ear and VIIIth cranial nerve disorders,Ear,N
84,1,Bladder discomfort,Bladder and urethral symptoms,Urinary tract signs and symptoms,Renal,N
84,2,Blood urine present,Urinalysis NEC,Renal and urinary tract investigations and urinalyses,Inv,N
85,1,Cough,Coughing and associated symptoms,Respiratory disorders NEC,Resp,N
85,2,Dyspnoea,Breathing abnormalities,Respiratory disorders NEC,Resp,N
85,3,Erythema,Erythemas,Epidermal and dermal conditions,Skin,N
85,4,Periorbital swelling,Ocular disorders NEC,Eye disorders NEC,Eye,N
86,1,General physical health deterioration,General signs and symptoms NEC,General system disorders NEC,Genrl,N
86,2,Sciatic nerve injury,Peripheral nerve injuries,Injuries NEC,Inj&P,N
87,1,Diarrhoea,Diarrhoea (excl infective),Gastrointestinal motility and defaecation conditions,Gastr,N
87,2,Pruritus,Pruritus NEC,Epidermal and dermal conditions,Skin,N
87,3,Rash,"Rashes, eruptions and exanthems NEC",Epidermal and dermal conditions,Skin,N
88,1,Dysarthria,Speech and language abnormalities,Neurological disorders NEC,Nerv,N
88,2,Lip pain,Oral soft tissue signs and symptoms,Oral soft tissue conditions,Gastr,N
89,1,Hepatic cirrhosis,Hepatic fibrosis and cirrhosis,Hepatic and hepatobiliary disorders,Hepat,Y
89,2,Liver disorder,Hepatic and hepatobiliary disorders NEC,Hepatic and hepatobiliary disorders,Hepat,N
90,1,Potentiating drug interaction,Interactions,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
90,2,Pulmonary embolism,Pulmonary thrombotic and embolic conditions,Pulmonary vascular disorders,Resp,N
91,1,Malignant neoplasm progression,Neoplasms malignant site unspecified NEC,Miscellaneous and site unspecified neoplasms malignant and unspecified,Neopl,N
91,2,Metastases to lymph nodes,Metastases to specified sites,Metastases,Neopl,N
92,1,Malignant neoplasm progression,Neoplasms malignant site unspecified NEC,Miscellaneous and site unspecified neoplasms malignant and unspecified,Neopl,N
92,2,Neutropenia,Neutropenias,White blood cell disorders,Blood,N
93,1,Breast cancer metastatic,Breast and nipple neoplasms malignant,Breast neoplasms malignant and unspecified (incl nipple),Neopl,N
93,2,General physical health deterioration,General signs and symptoms NEC,General system disorders NEC,Genrl,N
93,3,Jaundice,Cholestasis and jaundice,Hepatic and hepatobiliary disorders,Hepat,N
93,4,Malignant neoplasm progression,Neoplasms malignant site unspecified NEC,Miscellaneous and site unspecified neoplasms malignant and unspecified,Neopl,N
93,5,Metastases to bone,Metastases to specified sites,Metastases,Neopl,N
93,6,Metastases to liver,Metastases to specified sites,Metastases,Neopl,N
94,1,Fatigue,Asthenic conditions,General system disorders NEC,Genrl,N
94,2,Pain in extremity,Musculoskeletal and connective tissue pain and discomfort,Musculoskeletal and connective tissue disorders NEC,Musc,N
95,1,Bile duct stenosis,Obstructive bile duct disorders (excl neoplasms),Bile duct disorders,Hepat,N
95,2,Breast cancer metastatic,Breast and nipple neoplasms malignant,Breast neoplasms malignant and unspecified (incl nipple),Neopl,N
95,3,Jaundice,Cholestasis and jaundice,Hepatic and hepatobiliary disorders,Hepat,N
95,4,Malignant neoplasm progression,Neoplasms malignant site unspecified NEC,Miscellaneous and site unspecified neoplasms malignant and unspecified,Neopl,N
95,5,Metastases to bone,Metastases to specified sites,Metastases,Neopl,N
95,6,Metastases to liver,Metastases to specified sites,Metastases,Neopl,N
95,7,Metastases to lymph nodes,Metastases to specified sites,Metastases,Neopl,N
95,8,Rash,"Rashes, eruptions and exanthems NEC",Epidermal and dermal conditions,Skin,N
96,1,Disease progression,General signs and symptoms NEC,General system disorders NEC,Genrl,Y
96,2,Ejection fraction decreased,Cardiac function diagnostic procedures,Cardiac and vascular investigations (excl enzyme tests),Inv,N
96,3,Localised infection,Infections NEC,Infections - pathogen unspecified,Infec,N
97,1,Dry eye,Lacrimation disorders,Eye disorders NEC,Eye,N
97,2,Gastrooesophageal reflux disease,Gastrointestinal atonic and hypomotility disorders NEC,Gastrointestinal motility and defaecation conditions,Gastr,N
98,1,Decubitus ulcer,Skin injuries and mechanical dermatoses,Epidermal and dermal conditions,Skin,N
99,1,Breast cancer metastatic,Breast and nipple neoplasms malignant,Breast neoplasms malignant and unspecified (incl nipple),Neopl,N
99,2,Malignant neoplasm progression,Neoplasms malignant site unspecified NEC,Miscellaneous and site unspecified neoplasms malignant and unspecified,Neopl,N
100,1,Arthralgia,Joint related signs and symptoms,Joint disorders,Musc,N
100,2,Back pain,Musculoskeletal and connective tissue pain and discomfort,Musculoskeletal and connective tissue disorders NEC,Musc,N
100,3,Dyspnoea exertional,Breathing abnormalities,Respiratory disorders NEC,Resp,N
100,4,Fatigue,Asthenic conditions,General system disorders NEC,Genrl,N
100,5,Hypoaesthesia,Paraesthesias and dysaesthesias,Neurological disorders NEC,Nerv,N
101,1,Nausea,Nausea and vomiting symptoms,Gastrointestinal signs and symptoms,Gastr,N
102,1,Diarrhoea,Diarrhoea (excl infective),Gastrointestinal motility and defaecation conditions,Gastr,N
103,1,Alopecia,Alopecias,Skin appendage conditions,Skin,N
103,2,Back pain,Musculoskeletal and connective tissue pain and discomfort,Musculoskeletal and connective tissue disorders NEC,Musc,N
103,3,Dry mouth,Oral dryness and saliva altered,Salivary gland conditions,Gastr,N
103,4,Dyspnoea,Breathing abnormalities,Respiratory disorders NEC,Resp,N
103,5,Mouth ulceration,Stomatitis and ulceration,Oral soft tissue conditions,Gastr,N
103,6,Peripheral swelling,General signs and symptoms NEC,General system disorders NEC,Genrl,N
104,1,Diarrhoea,Diarrhoea (excl infective),Gastrointestinal motility and defaecation conditions,Gastr,N
104,2,Fatigue,Asthenic conditions,General system disorders NEC,Genrl,N
104,3,Nausea,Nausea and vomiting symptoms,Gastrointestinal signs and symptoms,Gastr,N
105,1,Pain in extremity,Musculoskeletal and connective tissue pain and discomfort,Musculoskeletal and connective tissue disorders NEC,Musc,N
106,1,Gingival bleeding,Gingival haemorrhages,Dental and gingival conditions,Gastr,N
106,2,Gingival pain,"Gingival disorders, signs and symptoms NEC",Dental and gingival conditions,Gastr,N
106,3,Pain in jaw,Bone related signs and symptoms,Bone disorders (excl congenital and fractures),Musc,N
106,4,Toothache,Dental pain and sensation disorders,Dental and gingival conditions,Gastr,N
107,1,Fatigue,Asthenic conditions,General system disorders NEC,Genrl,N
108,1,Coronavirus infection,Coronavirus infections,Viral infectious disorders,Infec,Y
109,1,Mouth ulceration,Stomatitis and ulceration,Oral soft tissue conditions,Gastr,N
109,2,Taste disorder,Sensory abnormalities NEC,Neurological disorders NEC,Nerv,N
110,1,Hypoaesthesia,Paraesthesias and dysaesthesias,Neurological disorders NEC,Nerv,N
110,2,Motor dysfunction,Dyskinesias and movement disorders NEC,Movement disorders (incl parkinsonism),Nerv,N
110,3,Muscle spasms,Muscle related signs and symptoms NEC,Muscle disorders,Musc,N
110,4,Neuropathy peripheral,Peripheral neuropathies NEC,Peripheral neuropathies,Nerv,N
110,5,Paraesthesia,Paraesthesias and dysaesthesias,Neurological disorders NEC,Nerv,N
110,6,Temperature intolerance,Feelings and sensations NEC,General system disorders NEC,Genrl,N
111,1,COVID-19,Coronavirus infections,Viral infectious disorders,Infec,N
111,2,Cough,Coughing and associated symptoms,Respiratory disorders NEC,Resp,N
111,3,Diarrhoea,Diarrhoea (excl infective),Gastrointestinal motility and defaecation conditions,Gastr,N
111,4,Dyspnoea,Breathing abnormalities,Respiratory disorders NEC,Resp,N
111,5,Neutrophil count decreased,White blood cell analyses,Haematology investigations (incl blood groups),Inv,N
111,6,Platelet count decreased,Platelet analyses,Haematology investigations (incl blood groups),Inv,N
111,7,Pyrexia,Febrile disorders,Body temperature conditions,Genrl,N
112,1,COVID-19,Coronavirus infections,Viral infectious disorders,Infec,N
112,2,Cough,Coughing and associated symptoms,Respiratory disorders NEC,Resp,N
112,3,Dyspnoea,Breathing abnormalities,Respiratory disorders NEC,Resp,N
112,4,Fatigue,Asthenic conditions,General system disorders NEC,Genrl,N
112,5,Neoplasm progression,Neoplasms unspecified malignancy and site unspecified NEC,Miscellaneous and site unspecified neoplasms malignant and unspecified,Neopl,N
112,6,Neutropenia,Neutropenias,White blood cell disorders,Blood,N
112,7,Pyrexia,Febrile disorders,Body temperature conditions,Genrl,N
113,1,Breast cancer metastatic,Breast and nipple neoplasms malignant,Breast neoplasms malignant and unspecified (incl nipple),Neopl,N
113,2,Fatigue,Asthenic conditions,General system disorders NEC,Genrl,N
113,3,Malignant neoplasm progression,Neoplasms malignant site unspecified NEC,Miscellaneous and site unspecified neoplasms malignant and unspecified,Neopl,N
113,4,Mediastinal disorder,Mediastinal disorders,Thoracic disorders (excl lung and pleura),Resp,N
113,5,Metastases to bone,Metastases to specified sites,Metastases,Neopl,N
113,6,Metastases to liver,Metastases to specified sites,Metastases,Neopl,N
113,7,PIK3CA-activated mutation,Gene mutations and other alterations NEC,"Chromosomal abnormalities, gene alterations and gene variants",Cong,N
113,8,Pleural effusion,Pneumothorax and pleural effusions NEC,Pleural disorders,Resp,N
114,1,Cough,Coughing and associated symptoms,Respiratory disorders NEC,Resp,N
114,2,Motion sickness,Inner ear signs and symptoms,Inner ear and VIIIth cranial nerve disorders,Ear,N
115,1,Injection site bruising,Injection site reactions,Administration site reactions,Genrl,N
115,2,Myocardial infarction,Ischaemic coronary artery disorders,Coronary artery disorders,Card,N
116,1,Death,Death and sudden death,Fatal outcomes,Genrl,Y
116,2,Pneumonitis,Lower respiratory tract inflammatory and immunologic conditions,Lower respiratory tract disorders (excl obstruction and infection),Resp,N
116,3,SARS-CoV-2 test negative,Virus identification and serology,Microbiology and serology investigations,Inv,N
117,1,Dyspnoea exertional,Breathing abnormalities,Respiratory disorders NEC,Resp,N
117,2,Nausea,Nausea and vomiting symptoms,Gastrointestinal signs and symptoms,Gastr,N
118,1,Pneumonia,Lower respiratory tract and lung infections,Infections - pathogen unspecified,Infec,N
118,2,Product administration interrupted,Product administration errors and issues,Medication errors and other product use errors and issues,Inj&P,N
119,1,Femoral neck fracture,Limb fractures and dislocations,Bone and joint injuries,Inj&P,N
120,1,Malignant neoplasm progression,Neoplasms malignant site unspecified NEC,Miscellaneous and site unspecified neoplasms malignant and unspecified,Neopl,N
120,2,Metastases to bone,Metastases to specified sites,Metastases,Neopl,N
121,1,Incorrect route of product administration,Product administration errors and issues,Medication errors and other product use errors and issues,Inj&P,N
121,2,Malignant neoplasm progression,Neoplasms malignant site unspecified NEC,Miscellaneous and site unspecified neoplasms malignant and unspecified,Neopl,N
121,3,Malignant neoplasm progression,Neoplasms malignant site unspecified NEC,Miscellaneous and site unspecified neoplasms malignant and unspecified,Neopl,N
121,4,Malignant neoplasm progression,Neoplasms malignant site unspecified NEC,Miscellaneous and site unspecified neoplasms malignant and unspecified,Neopl,N
122,1,Abdominal pain,Gastrointestinal and abdominal pains (excl oral and throat),Gastrointestinal signs and symptoms,Gastr,N
122,2,Constipation,Gastrointestinal atonic and hypomotility disorders NEC,Gastrointestinal motility and defaecation conditions,Gastr,N
122,3,Fatigue,Asthenic conditions,General system disorders NEC,Genrl,N
123,1,Abdominal pain,Gastrointestinal and abdominal pains (excl oral and throat),Gastrointestinal signs and symptoms,Gastr,N
123,2,Abdominal pain lower,Gastrointestinal and abdominal pains (excl oral and throat),Gastrointestinal signs and symptoms,Gastr,N
123,3,Asthenia,Asthenic conditions,General system disorders NEC,Genrl,N
123,4,Cellulitis,Bacterial infections NEC,Bacterial infectious disorders,Infec,N
123,5,Cerebrovascular accident,Central nervous system haemorrhages and cerebrovascular accidents,Central nervous system vascular disorders,Nerv,N
123,6,Cough,Coughing and associated symptoms,Respiratory disorders NEC,Resp,N
123,7,Disease progression,General signs and symptoms NEC,General system disorders NEC,Genrl,Y
123,8,Ejection fraction decreased,Cardiac function diagnostic procedures,Cardiac and vascular investigations (excl enzyme tests),Inv,N
123,9,Headache,Headaches NEC,Headaches,Nerv,N
123,10,Headache,Headaches NEC,Headaches,Nerv,N
123,11,Hypertension,Vascular hypertensive disorders NEC,Vascular hypertensive disorders,Vasc,N
123,12,Lower respiratory tract infection,Lower respiratory tract and lung infections,Infections - pathogen unspecified,Infec,N
123,13,Mouth swelling,Oral soft tissue swelling and oedema,Oral soft tissue conditions,Gastr,N
123,14,Nausea,Nausea and vomiting symptoms,Gastrointestinal signs and symptoms,Gastr,N
123,15,Pain in extremity,Musculoskeletal and connective tissue pain and discomfort,Musculoskeletal and connective tissue disorders NEC,Musc,N
123,16,Superinfection,Infections NEC,Infections - pathogen unspecified,Infec,N
123,17,Swelling face,General signs and symptoms NEC,General system disorders NEC,Genrl,N
123,18,Urinary tract infection,Urinary tract infections,Infections - pathogen unspecified,Infec,N
123,19,Vomiting,Nausea and vomiting symptoms,Gastrointestinal signs and symptoms,Gastr,N
124,1,Sciatica,Lumbar spinal cord and nerve root disorders,Spinal cord and nerve root disorders,Nerv,N
125,1,Malignant neoplasm progression,Neoplasms malignant site unspecified NEC,Miscellaneous and site unspecified neoplasms malignant and unspecified,Neopl,N
125,2,Metastases to peritoneum,Metastases to specified sites,Metastases,Neopl,N
125,3,Off label use,Off label uses,Off label uses and intentional product misuses/use issues,Inj&P,N
125,4,PIK3CA-activated mutation,Gene mutations and other alterations NEC,"Chromosomal abnormalities, gene alterations and gene variants",Cong,N
126,1,Hot flush,Peripheral vascular disorders NEC,Vascular disorders NEC,Vasc,N
126,2,Hyperhidrosis,Apocrine and eccrine gland disorders,Skin appendage conditions,Skin,N
127,1,Liver injury,Hepatocellular damage and hepatitis NEC,Hepatic and hepatobiliary disorders,Hepat,N
128,1,Rash,"Rashes, eruptions and exanthems NEC",Epidermal and dermal conditions,Skin,N
129,1,Aspartate aminotransferase increased,Hepatobiliary function diagnostic procedures,Hepatobiliary investigations,Inv,N
129,2,Hepatic cirrhosis,Hepatic fibrosis and cirrhosis,Hepatic and hepatobiliary disorders,Hepat,N
129,3,Stenosis,General signs and symptoms NEC,General system disorders NEC,Genrl,N
130,1,Nausea,Nausea and vomiting symptoms,Gastrointestinal signs and symptoms,Gastr,N
131,1,Sciatica,Lumbar spinal cord and nerve root disorders,Spinal cord and nerve root disorders,Nerv,N
132,1,Back pain,Musculoskeletal and connective tissue pain and discomfort,Musculoskeletal and connective tissue disorders NEC,Musc,N
132,2,Blood glucose increased,Carbohydrate tolerance analyses (incl diabetes),"Metabolic, nutritional and blood gas investigations",Inv,N
132,3,Diarrhoea,Diarrhoea (excl infective),Gastrointestinal motility and defaecation conditions,Gastr,N
132,4,Metastases to bone,Metastases to specified sites,Metastases,Neopl,N
132,5,Nausea,Nausea and vomiting symptoms,Gastrointestinal signs and symptoms,Gastr,N
133,1,Back pain,Musculoskeletal and connective tissue pain and discomfort,Musculoskeletal and connective tissue disorders NEC,Musc,N
133,2,Dysphagia,Gastrointestinal signs and symptoms NEC,Gastrointestinal signs and symptoms,Gastr,N
133,3,Dyspnoea,Breathing abnormalities,Respiratory disorders NEC,Resp,N
133,4,Fatigue,Asthenic conditions,General system disorders NEC,Genrl,N
133,5,Hypoaesthesia,Paraesthesias and dysaesthesias,Neurological disorders NEC,Nerv,N
133,6,Necrosis,Necrosis NEC,Tissue disorders NEC,Genrl,N
133,7,Pain in jaw,Bone related signs and symptoms,Bone disorders (excl congenital and fractures),Musc,N
133,8,Paraesthesia,Paraesthesias and dysaesthesias,Neurological disorders NEC,Nerv,N
134,1,Abdominal lymphadenopathy,Lymphatic system disorders NEC,"Spleen, lymphatic and reticuloendothelial system disorders",Blood,N
134,2,Breast cancer metastatic,Breast and nipple neoplasms malignant,Breast neoplasms malignant and unspecified (incl nipple),Neopl,N
134,3,Carcinoid tumour pulmonary,Carcinoid tumours,Endocrine neoplasms malignant and unspecified,Neopl,N
134,4,Hepatic cancer,Hepatic neoplasms malignant,Hepatobiliary neoplasms malignant and unspecified,Neopl,N
134,5,Malignant neoplasm progression,Neoplasms malignant site unspecified NEC,Miscellaneous and site unspecified neoplasms malignant and unspecified,Neopl,N
134,6,Metastases to liver,Metastases to specified sites,Metastases,Neopl,N
134,7,Pleural neoplasm,Respiratory tract and pleural neoplasms malignancy unspecified NEC,Respiratory and mediastinal neoplasms malignant and unspecified,Neopl,N
134,8,Toxicity to various agents,Poisoning and toxicity,"Exposures, chemical injuries and poisoning",Inj&P,N
135,1,Asthenia,Asthenic conditions,General system disorders NEC,Genrl,N
135,2,Infection,Infections NEC,Infections - pathogen unspecified,Infec,N
136,1,Volvulus,Gastrointestinal stenosis and obstruction NEC,Gastrointestinal stenosis and obstruction,Gastr,N
137,1,Incorrect dose administered,Product administration errors and issues,Medication errors and other product use errors and issues,Inj&P,N
137,2,Injection site bruising,Injection site reactions,Administration site reactions,Genrl,N
137,3,Injection site hypoaesthesia,Injection site reactions,Administration site reactions,Genrl,N
137,4,Pain in extremity,Musculoskeletal and connective tissue pain and discomfort,Musculoskeletal and connective tissue disorders NEC,Musc,N
137,5,Sciatic nerve injury,Peripheral nerve injuries,Injuries NEC,Inj&P,N
138,1,Dry skin,Dermal and epidermal conditions NEC,Epidermal and dermal conditions,Skin,N
138,2,Fatigue,Asthenic conditions,General system disorders NEC,Genrl,N
138,3,Pain in extremity,Musculoskeletal and connective tissue pain and discomfort,Musculoskeletal and connective tissue disorders NEC,Musc,N
138,4,Skin discolouration,Dermal and epidermal conditions NEC,Epidermal and dermal conditions,Skin,N
139,1,Arthralgia,Joint related signs and symptoms,Joint disorders,Musc,N
139,2,Asthenia,Asthenic conditions,General system disorders NEC,Genrl,N
139,3,Balance disorder,Coordination and balance disturbances,Neurological disorders NEC,Nerv,N
139,4,Fatigue,Asthenic conditions,General system disorders NEC,Genrl,N
139,5,Hypoaesthesia,Paraesthesias and dysaesthesias,Neurological disorders NEC,Nerv,N
139,6,Muscular weakness,Muscle weakness conditions,Muscle disorders,Musc,N
139,7,Myalgia,Muscle pains,Muscle disorders,Musc,N
139,8,Sciatica,Lumbar spinal cord and nerve root disorders,Spinal cord and nerve root disorders,Nerv,N
139,9,Urinary tract infection,Urinary tract infections,Infections - pathogen unspecified,Infec,N
140,1,Pneumonitis,Lower respiratory tract inflammatory and immunologic conditions,Lower respiratory tract disorders (excl obstruction and infection),Resp,N
141,1,Acute hepatic failure,Hepatic failure and associated disorders,Hepatic and hepatobiliary disorders,Hepat,Y
141,2,Brain herniation,Cerebral injuries NEC,Injuries NEC,Inj&P,N
141,3,Brain oedema,Increased intracranial pressure disorders,Increased intracranial pressure and hydrocephalus,Nerv,N
141,4,Cerebellar haemorrhage,Central nervous system haemorrhages and cerebrovascular accidents,Central nervous system vascular disorders,Nerv,N
141,5,Cerebral disorder,Nervous system disorders NEC,Neurological disorders NEC,Nerv,N
141,6,Haemorrhagic infarction,Non-site specific necrosis and vascular insufficiency NEC,"Arteriosclerosis, stenosis, vascular insufficiency and necrosis",Vasc,N
141,7,Headache,Headaches NEC,Headaches,Nerv,N
141,8,Hyperpyrexia,Febrile disorders,Body temperature conditions,Genrl,N
141,9,Intracranial pressure increased,Increased intracranial pressure disorders,Increased intracranial pressure and hydrocephalus,Nerv,N
141,10,Jaundice,Cholestasis and jaundice,Hepatic and hepatobiliary disorders,Hepat,N
141,11,Portal vein thrombosis,Hepatic vascular disorders,Hepatic and hepatobiliary disorders,Hepat,N
141,12,Pulmonary congestion,Pulmonary oedemas,Lower respiratory tract disorders (excl obstruction and infection),Resp,N
141,13,Pulmonary oedema,Pulmonary oedemas,Lower respiratory tract disorders (excl obstruction and infection),Resp,N
141,14,Vision blurred,Visual disorders NEC,Vision disorders,Eye,N
142,1,Acute hepatic failure,Hepatic failure and associated disorders,Hepatic and hepatobiliary disorders,Hepat,Y
142,2,Portal vein thrombosis,Hepatic vascular disorders,Hepatic and hepatobiliary disorders,Hepat,N
143,1,Volvulus,Gastrointestinal stenosis and obstruction NEC,Gastrointestinal stenosis and obstruction,Gastr,N
144,1,Ascites,Peritoneal and retroperitoneal disorders,Peritoneal and retroperitoneal conditions,Gastr,N
144,2,Bone disorder,Bone disorders NEC,Bone disorders (excl congenital and fractures),Musc,N
144,3,Bone lesion,Bone disorders NEC,Bone disorders (excl congenital and fractures),Musc,N
144,4,Invasive lobular breast carcinoma,Breast and nipple neoplasms malignant,Breast neoplasms malignant and unspecified (incl nipple),Neopl,N
144,5,Malignant neoplasm progression,Neoplasms malignant site unspecified NEC,Miscellaneous and site unspecified neoplasms malignant and unspecified,Neopl,N
144,6,Tumour marker increased,Cell marker analyses,Cytogenetic investigations and genetic analyses,Inv,N
144,7,Uterine mass,Uterine disorders NEC,"Uterine, pelvic and broad ligament disorders",Repro,N
145,1,Disease progression,General signs and symptoms NEC,General system disorders NEC,Genrl,Y
145,2,Ejection fraction decreased,Cardiac function diagnostic procedures,Cardiac and vascular investigations (excl enzyme tests),Inv,N
145,3,Localised infection,Infections NEC,Infections - pathogen unspecified,Infec,N
146,1,Crying,General signs and symptoms NEC,General system disorders NEC,Genrl,N
146,2,Hypoaesthesia,Paraesthesias and dysaesthesias,Neurological disorders NEC,Nerv,N
147,1,Erythema multiforme,Bullous conditions,Epidermal and dermal conditions,Skin,N
148,1,Diarrhoea,Diarrhoea (excl infective),Gastrointestinal motility and defaecation conditions,Gastr,N
149,1,Rash erythematous,"Rashes, eruptions and exanthems NEC",Epidermal and dermal conditions,Skin,N
149,2,Skin exfoliation,Exfoliative conditions,Epidermal and dermal conditions,Skin,N
150,1,Portal vein thrombosis,Hepatic vascular disorders,Hepatic and hepatobiliary disorders,Hepat,N
151,1,Acute hepatic failure,Hepatic failure and associated disorders,Hepatic and hepatobiliary disorders,Hepat,Y
151,2,Brain oedema,Increased intracranial pressure disorders,Increased intracranial pressure and hydrocephalus,Nerv,N
151,3,Portal vein thrombosis,Hepatic vascular disorders,Hepatic and hepatobiliary disorders,Hepat,N
152,1,Anaemia,Anaemias NEC,Anaemias nonhaemolytic and marrow depression,Blood,N
152,2,Brain herniation,Cerebral injuries NEC,Injuries NEC,Inj&P,N
152,3,Brain oedema,Increased intracranial pressure disorders,Increased intracranial pressure and hydrocephalus,Nerv,N
152,4,Brain oedema,Increased intracranial pressure disorders,Increased intracranial pressure and hydrocephalus,Nerv,N
152,5,Disease progression,General signs and symptoms NEC,General system disorders NEC,Genrl,N
152,6,Haemolysis,Haemolyses NEC,Haemolyses and related conditions,Blood,N
152,7,Hepatic failure,Hepatic failure and associated disorders,Hepatic and hepatobiliary disorders,Hepat,N
152,8,Hepatic failure,Hepatic failure and associated disorders,Hepatic and hepatobiliary disorders,Hepat,N
152,9,Multiple organ dysfunction syndrome,General signs and symptoms NEC,General system disorders NEC,Genrl,Y
152,10,Non-cirrhotic portal hypertension,Hepatic vascular disorders,Hepatic and hepatobiliary disorders,Hepat,N
152,11,Portal vein thrombosis,Hepatic vascular disorders,Hepatic and hepatobiliary disorders,Hepat,N
152,12,Thrombosis,Non-site specific embolism and thrombosis,Embolism and thrombosis,Vasc,N
153,1,Anaemia,Anaemias NEC,Anaemias nonhaemolytic and marrow depression,Blood,N
153,2,Brain herniation,Cerebral injuries NEC,Injuries NEC,Inj&P,N
153,3,Brain oedema,Increased intracranial pressure disorders,Increased intracranial pressure and hydrocephalus,Nerv,N
153,4,Haemolysis,Haemolyses NEC,Haemolyses and related conditions,Blood,N
153,5,Hepatic failure,Hepatic failure and associated disorders,Hepatic and hepatobiliary disorders,Hepat,Y
153,6,Non-cirrhotic portal hypertension,Hepatic vascular disorders,Hepatic and hepatobiliary disorders,Hepat,N
154,1,Arthralgia,Joint related signs and symptoms,Joint disorders,Musc,N
154,2,Fatigue,Asthenic conditions,General system disorders NEC,Genrl,N
154,3,Hot flush,Peripheral vascular disorders NEC,Vascular disorders NEC,Vasc,N
155,1,Rash,"Rashes, eruptions and exanthems NEC",Epidermal and dermal conditions,Skin,N
156,1,Hypoaesthesia,Paraesthesias and dysaesthesias,Neurological disorders NEC,Nerv,N
157,1,Platelet count decreased,Platelet analyses,Haematology investigations (incl blood groups),Inv,N
158,1,Anaphylactic reaction,Anaphylactic and anaphylactoid responses,Allergic conditions,Immun,N
159,1,Diarrhoea,Diarrhoea (excl infective),Gastrointestinal motility and defaecation conditions,Gastr,N
159,2,Fatigue,Asthenic conditions,General system disorders NEC,Genrl,N
159,3,Stress,Anxiety symptoms,Anxiety disorders and symptoms,Psych,N
160,1,Fatigue,Asthenic conditions,General system disorders NEC,Genrl,N
160,2,Nausea,Nausea and vomiting symptoms,Gastrointestinal signs and symptoms,Gastr,N
161,1,Adnexa uteri mass,Pelvis and broad ligament disorders NEC,"Uterine, pelvic and broad ligament disorders",Repro,N
161,2,Neoplasm progression,Neoplasms unspecified malignancy and site unspecified NEC,Miscellaneous and site unspecified neoplasms malignant and unspecified,Neopl,N
161,3,Small intestinal obstruction,Duodenal and small intestinal stenosis and obstruction,Gastrointestinal stenosis and obstruction,Gastr,N
161,4,Small intestinal perforation,Intestinal ulcers and perforation NEC,Gastrointestinal ulceration and perforation,Gastr,N
161,5,Thrombocytopenia,Thrombocytopenias,Platelet disorders,Blood,N
162,1,Arthralgia,Joint related signs and symptoms,Joint disorders,Musc,N
162,2,Diarrhoea,Diarrhoea (excl infective),Gastrointestinal motility and defaecation conditions,Gastr,N
162,3,Drug tolerance decreased,Therapeutic and nontherapeutic responses,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
162,4,Dry eye,Lacrimation disorders,Eye disorders NEC,Eye,N
162,5,Dyspepsia,Dyspeptic signs and symptoms,Gastrointestinal signs and symptoms,Gastr,N
162,6,Fatigue,Asthenic conditions,General system disorders NEC,Genrl,N
162,7,Hepatotoxicity,Hepatocellular damage and hepatitis NEC,Hepatic and hepatobiliary disorders,Hepat,N
162,8,Hypoaesthesia,Paraesthesias and dysaesthesias,Neurological disorders NEC,Nerv,N
162,9,Insomnia,Disturbances in initiating and maintaining sleep,Sleep disorders and disturbances,Psych,N
162,10,Lacrimation increased,Lacrimation disorders,Eye disorders NEC,Eye,N
162,11,Metastases to bone,Metastases to specified sites,Metastases,Neopl,N
162,12,Metastases to lung,Metastases to specified sites,Metastases,Neopl,N
162,13,Mucosal toxicity,Mucosal findings abnormal,General system disorders NEC,Genrl,N
162,14,Pruritus,Pruritus NEC,Epidermal and dermal conditions,Skin,N
162,15,Rash,"Rashes, eruptions and exanthems NEC",Epidermal and dermal conditions,Skin,N
162,16,Skin toxicity,Dermal and epidermal conditions NEC,Epidermal and dermal conditions,Skin,N
163,1,Arthralgia,Joint related signs and symptoms,Joint disorders,Musc,N
163,2,Cough,Coughing and associated symptoms,Respiratory disorders NEC,Resp,N
163,3,Diabetes mellitus,Diabetes mellitus (incl subtypes),Glucose metabolism disorders (incl diabetes mellitus),Metab,N
163,4,Dry skin,Dermal and epidermal conditions NEC,Epidermal and dermal conditions,Skin,N
163,5,Fatigue,Asthenic conditions,General system disorders NEC,Genrl,N
163,6,Glossodynia,Tongue signs and symptoms,Tongue conditions,Gastr,N
163,7,Malignant neoplasm progression,Neoplasms malignant site unspecified NEC,Miscellaneous and site unspecified neoplasms malignant and unspecified,Neopl,N
163,8,Metastases to bone,Metastases to specified sites,Metastases,Neopl,N
163,9,Metastases to breast,Metastases to specified sites,Metastases,Neopl,N
163,10,Metastases to liver,Metastases to specified sites,Metastases,Neopl,N
163,11,Oral pain,Oral soft tissue signs and symptoms,Oral soft tissue conditions,Gastr,N
163,12,Pain in extremity,Musculoskeletal and connective tissue pain and discomfort,Musculoskeletal and connective tissue disorders NEC,Musc,N
163,13,Pelvic pain,Reproductive tract signs and symptoms NEC,Reproductive tract disorders NEC,Repro,N
163,14,Vaginal discharge,Vulvovaginal signs and symptoms,Vulvovaginal disorders (excl infections and inflammations),Repro,N
164,1,Chest discomfort,Pain and discomfort NEC,General system disorders NEC,Genrl,N
164,2,Flushing,Peripheral vascular disorders NEC,Vascular disorders NEC,Vasc,N
164,3,Neck pain,Musculoskeletal and connective tissue pain and discomfort,Musculoskeletal and connective tissue disorders NEC,Musc,N
165,1,Discomfort,Pain and discomfort NEC,General system disorders NEC,Genrl,N
165,2,Muscle injury,"Muscle, tendon and ligament injuries",Injuries NEC,Inj&P,N
165,3,Muscle tightness,Muscle related signs and symptoms NEC,Muscle disorders,Musc,N
165,4,Product use in unapproved indication,"Medication errors, product use errors and issues NEC",Medication errors and other product use errors and issues,Inj&P,N
166,1,Blood glucose increased,Carbohydrate tolerance analyses (incl diabetes),"Metabolic, nutritional and blood gas investigations",Inv,N
166,2,Decreased appetite,Appetite disorders,Appetite and general nutritional disorders,Metab,N
166,3,Dry mouth,Oral dryness and saliva altered,Salivary gland conditions,Gastr,N
166,4,Fatigue,Asthenic conditions,General system disorders NEC,Genrl,N
166,5,Nausea,Nausea and vomiting symptoms,Gastrointestinal signs and symptoms,Gastr,N
166,6,Neuropathy peripheral,Peripheral neuropathies NEC,Peripheral neuropathies,Nerv,N
166,7,Vulvovaginal candidiasis,Candida infections,Fungal infectious disorders,Infec,N
167,1,Cough,Coughing and associated symptoms,Respiratory disorders NEC,Resp,N
167,2,Dyspepsia,Dyspeptic signs and symptoms,Gastrointestinal signs and symptoms,Gastr,N
167,3,Hepatic failure,Hepatic failure and associated disorders,Hepatic and hepatobiliary disorders,Hepat,N
167,4,Jaundice,Cholestasis and jaundice,Hepatic and hepatobiliary disorders,Hepat,N
167,5,Pruritus,Pruritus NEC,Epidermal and dermal conditions,Skin,N
168,1,Malignant neoplasm progression,Neoplasms malignant site unspecified NEC,Miscellaneous and site unspecified neoplasms malignant and unspecified,Neopl,N
169,1,Cough,Coughing and associated symptoms,Respiratory disorders NEC,Resp,N
170,1,Gait disturbance,Gait disturbances,General system disorders NEC,Genrl,N
170,2,Illness,General signs and symptoms NEC,General system disorders NEC,Genrl,N
170,3,Injection site pain,Injection site reactions,Administration site reactions,Genrl,N
170,4,Injection site swelling,Injection site reactions,Administration site reactions,Genrl,N
170,5,Intentional dose omission,Intentional product use issues,Off label uses and intentional product misuses/use issues,Inj&P,N
170,6,Neuralgia,Sensory abnormalities NEC,Neurological disorders NEC,Nerv,N
170,7,Pain in extremity,Musculoskeletal and connective tissue pain and discomfort,Musculoskeletal and connective tissue disorders NEC,Musc,N
171,1,Constipation,Gastrointestinal atonic and hypomotility disorders NEC,Gastrointestinal motility and defaecation conditions,Gastr,N
171,2,Fatigue,Asthenic conditions,General system disorders NEC,Genrl,N
171,3,Rash,"Rashes, eruptions and exanthems NEC",Epidermal and dermal conditions,Skin,N
172,1,Pain,Pain and discomfort NEC,General system disorders NEC,Genrl,N
173,1,Breast cancer metastatic,Breast and nipple neoplasms malignant,Breast neoplasms malignant and unspecified (incl nipple),Neopl,N
173,2,Chest discomfort,Pain and discomfort NEC,General system disorders NEC,Genrl,N
173,3,Invasive ductal breast carcinoma,Breast and nipple neoplasms malignant,Breast neoplasms malignant and unspecified (incl nipple),Neopl,N
173,4,Malignant neoplasm progression,Neoplasms malignant site unspecified NEC,Miscellaneous and site unspecified neoplasms malignant and unspecified,Neopl,N
173,5,Metastases to adrenals,Metastases to specified sites,Metastases,Neopl,N
173,6,Metastases to bone,Metastases to specified sites,Metastases,Neopl,N
173,7,Metastases to liver,Metastases to specified sites,Metastases,Neopl,N
173,8,Metastases to lung,Metastases to specified sites,Metastases,Neopl,N
174,1,Fatigue,Asthenic conditions,General system disorders NEC,Genrl,N
174,2,Nausea,Nausea and vomiting symptoms,Gastrointestinal signs and symptoms,Gastr,N
175,1,Diarrhoea,Diarrhoea (excl infective),Gastrointestinal motility and defaecation conditions,Gastr,N
176,1,Carbohydrate antigen 15-3 increased,Cell marker analyses,Cytogenetic investigations and genetic analyses,Inv,N
176,2,Dysphagia,Gastrointestinal signs and symptoms NEC,Gastrointestinal signs and symptoms,Gastr,N
176,3,Wrong technique in product usage process,"Medication errors, product use errors and issues NEC",Medication errors and other product use errors and issues,Inj&P,N
177,1,Nausea,Nausea and vomiting symptoms,Gastrointestinal signs and symptoms,Gastr,N
177,2,Rash maculo-papular,"Rashes, eruptions and exanthems NEC",Epidermal and dermal conditions,Skin,N
178,1,Hyperglycaemia,Hyperglycaemic conditions NEC,Glucose metabolism disorders (incl diabetes mellitus),Metab,N
178,2,Nausea,Nausea and vomiting symptoms,Gastrointestinal signs and symptoms,Gastr,N
178,3,Rash,"Rashes, eruptions and exanthems NEC",Epidermal and dermal conditions,Skin,N
179,1,COVID-19,Coronavirus infections,Viral infectious disorders,Infec,N
179,2,Central nervous system lesion,Nervous system disorders NEC,Neurological disorders NEC,Nerv,N
179,3,Decreased appetite,Appetite disorders,Appetite and general nutritional disorders,Metab,N
179,4,Depressed mood,Mood alterations with depressive symptoms,Depressed mood disorders and disturbances,Psych,N
179,5,Diarrhoea,Diarrhoea (excl infective),Gastrointestinal motility and defaecation conditions,Gastr,N
179,6,Dizziness,Neurological signs and symptoms NEC,Neurological disorders NEC,Nerv,N
179,7,Fatigue,Asthenic conditions,General system disorders NEC,Genrl,N
179,8,Gait disturbance,Gait disturbances,General system disorders NEC,Genrl,N
179,9,Headache,Headaches NEC,Headaches,Nerv,N
179,10,Hyperglycaemia,Hyperglycaemic conditions NEC,Glucose metabolism disorders (incl diabetes mellitus),Metab,N
179,11,Metastases to bone,Metastases to specified sites,Metastases,Neopl,N
179,12,Metastases to chest wall,Metastases to specified sites,Metastases,Neopl,N
179,13,Metastases to liver,Metastases to specified sites,Metastases,Neopl,N
179,14,Metastases to lymph nodes,Metastases to specified sites,Metastases,Neopl,N
179,15,Metastases to pancreas,Metastases to specified sites,Metastases,Neopl,N
179,16,Movement disorder,Dyskinesias and movement disorders NEC,Movement disorders (incl parkinsonism),Nerv,N
179,17,Muscle atrophy,Muscle related signs and symptoms NEC,Muscle disorders,Musc,N
179,18,Nausea,Nausea and vomiting symptoms,Gastrointestinal signs and symptoms,Gastr,N
179,19,Polydipsia,Fluid intake increased,Electrolyte and fluid balance conditions,Metab,N
179,20,Swelling face,General signs and symptoms NEC,General system disorders NEC,Genrl,N
179,21,Tumour marker increased,Cell marker analyses,Cytogenetic investigations and genetic analyses,Inv,N
180,1,Tenderness,Pain and discomfort NEC,General system disorders NEC,Genrl,N
181,1,Malignant neoplasm progression,Neoplasms malignant site unspecified NEC,Miscellaneous and site unspecified neoplasms malignant and unspecified,Neopl,N
182,1,Malignant neoplasm progression,Neoplasms malignant site unspecified NEC,Miscellaneous and site unspecified neoplasms malignant and unspecified,Neopl,N
183,1,Weight decreased,Physical examination procedures and organ system status,Physical examination and organ system status topics,Inv,N
184,1,Nausea,Nausea and vomiting symptoms,Gastrointestinal signs and symptoms,Gastr,N
185,1,Fatigue,Asthenic conditions,General system disorders NEC,Genrl,N
185,2,Neuropathy peripheral,Peripheral neuropathies NEC,Peripheral neuropathies,Nerv,N
186,1,Hormone receptor positive HER2 negative breast cancer,Breast and nipple neoplasms malignant,Breast neoplasms malignant and unspecified (incl nipple),Neopl,N
186,2,Malignant neoplasm progression,Neoplasms malignant site unspecified NEC,Miscellaneous and site unspecified neoplasms malignant and unspecified,Neopl,N
187,1,Pulmonary pain,Lower respiratory tract signs and symptoms,Respiratory tract signs and symptoms,Resp,N
188,1,Malignant neoplasm progression,Neoplasms malignant site unspecified NEC,Miscellaneous and site unspecified neoplasms malignant and unspecified,Neopl,N
189,1,Diarrhoea,Diarrhoea (excl infective),Gastrointestinal motility and defaecation conditions,Gastr,N
189,2,Fatigue,Asthenic conditions,General system disorders NEC,Genrl,N
189,3,Malignant neoplasm progression,Neoplasms malignant site unspecified NEC,Miscellaneous and site unspecified neoplasms malignant and unspecified,Neopl,N
189,4,Rash,"Rashes, eruptions and exanthems NEC",Epidermal and dermal conditions,Skin,N
190,1,Drug intolerance,Therapeutic and nontherapeutic responses,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
190,2,Malaise,Asthenic conditions,General system disorders NEC,Genrl,N
190,3,Metastases to bone,Metastases to specified sites,Metastases,Neopl,N
190,4,Metastases to liver,Metastases to specified sites,Metastases,Neopl,N
190,5,Metastases to lung,Metastases to specified sites,Metastases,Neopl,N
190,6,Metastases to spinal cord,Metastases to specified sites,Metastases,Neopl,N
190,7,Metastatic neoplasm,Neoplasms malignant site unspecified NEC,Miscellaneous and site unspecified neoplasms malignant and unspecified,Neopl,N
190,8,Neuropathy peripheral,Peripheral neuropathies NEC,Peripheral neuropathies,Nerv,N
190,9,Radiculopathy,Spinal cord and nerve root disorders NEC,Spinal cord and nerve root disorders,Nerv,N
190,10,Tumour flare,Oncologic complications and emergencies,Neoplasm related morbidities,Neopl,N
191,1,Malignant neoplasm progression,Neoplasms malignant site unspecified NEC,Miscellaneous and site unspecified neoplasms malignant and unspecified,Neopl,N
192,1,Blood alkaline phosphatase increased,Tissue enzyme analyses NEC,Enzyme investigations NEC,Inv,N
192,2,Drug ineffective,Therapeutic and nontherapeutic responses,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
192,3,Malignant neoplasm progression,Neoplasms malignant site unspecified NEC,Miscellaneous and site unspecified neoplasms malignant and unspecified,Neopl,N
192,4,Neutrophil count increased,White blood cell analyses,Haematology investigations (incl blood groups),Inv,N
193,1,Malignant neoplasm progression,Neoplasms malignant site unspecified NEC,Miscellaneous and site unspecified neoplasms malignant and unspecified,Neopl,N
193,2,Treatment failure,Therapeutic and nontherapeutic responses,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
194,1,Malignant neoplasm progression,Neoplasms malignant site unspecified NEC,Miscellaneous and site unspecified neoplasms malignant and unspecified,Neopl,N
195,1,Malignant neoplasm progression,Neoplasms malignant site unspecified NEC,Miscellaneous and site unspecified neoplasms malignant and unspecified,Neopl,N
196,1,Hyperglycaemia,Hyperglycaemic conditions NEC,Glucose metabolism disorders (incl diabetes mellitus),Metab,N
196,2,Rash,"Rashes, eruptions and exanthems NEC",Epidermal and dermal conditions,Skin,N
197,1,Toothache,Dental pain and sensation disorders,Dental and gingival conditions,Gastr,N
198,1,Hyperglycaemia,Hyperglycaemic conditions NEC,Glucose metabolism disorders (incl diabetes mellitus),Metab,N
199,1,Metastases to liver,Metastases to specified sites,Metastases,Neopl,N
199,2,Metastases to lung,Metastases to specified sites,Metastases,Neopl,N
199,3,Metastases to lymph nodes,Metastases to specified sites,Metastases,Neopl,N
199,4,Metastases to pleura,Metastases to specified sites,Metastases,Neopl,N
200,1,Carbohydrate antigen 15-3 increased,Cell marker analyses,Cytogenetic investigations and genetic analyses,Inv,N
200,2,Diarrhoea,Diarrhoea (excl infective),Gastrointestinal motility and defaecation conditions,Gastr,N
200,3,Electrocardiogram QT prolonged,ECG investigations,Cardiac and vascular investigations (excl enzyme tests),Inv,N
200,4,Metastases to liver,Metastases to specified sites,Metastases,Neopl,N
200,5,Neutropenia,Neutropenias,White blood cell disorders,Blood,N
201,1,Invasive ductal breast carcinoma,Breast and nipple neoplasms malignant,Breast neoplasms malignant and unspecified (incl nipple),Neopl,N
201,2,Malignant neoplasm progression,Neoplasms malignant site unspecified NEC,Miscellaneous and site unspecified neoplasms malignant and unspecified,Neopl,N
201,3,Malignant pleural effusion,Pleural neoplasms,Pleural disorders,Resp,N
201,4,Metastases to bone,Metastases to specified sites,Metastases,Neopl,N
201,5,Metastases to nervous system,Metastases to specified sites,Metastases,Neopl,N
201,6,Pleural thickening,Pleural conditions NEC,Pleural disorders,Resp,N
201,7,Pulmonary mass,Respiratory tract disorders NEC,Respiratory disorders NEC,Resp,N
201,8,Pulmonary septal thickening,Lower respiratory tract signs and symptoms,Respiratory tract signs and symptoms,Resp,N
202,1,Carbohydrate antigen 15-3 increased,Cell marker analyses,Cytogenetic investigations and genetic analyses,Inv,N
202,2,Haemoglobin abnormal,Red blood cell analyses,Haematology investigations (incl blood groups),Inv,N
202,3,Platelet disorder,Platelet disorders NEC,Platelet disorders,Blood,N
202,4,White blood cell count abnormal,White blood cell analyses,Haematology investigations (incl blood groups),Inv,N
203,1,Arthralgia,Joint related signs and symptoms,Joint disorders,Musc,N
203,2,Fatigue,Asthenic conditions,General system disorders NEC,Genrl,N
204,1,Acquired gene mutation,Gene mutations and other alterations NEC,"Chromosomal abnormalities, gene alterations and gene variants",Cong,N
204,2,BRCA2 gene mutation,Gene mutations and other alterations NEC,"Chromosomal abnormalities, gene alterations and gene variants",Cong,N
204,3,COVID-19,Coronavirus infections,Viral infectious disorders,Infec,N
204,4,Malignant neoplasm progression,Neoplasms malignant site unspecified NEC,Miscellaneous and site unspecified neoplasms malignant and unspecified,Neopl,N
204,5,Metastases to liver,Metastases to specified sites,Metastases,Neopl,N
205,1,Adverse event,Therapeutic and nontherapeutic responses,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
205,2,Pain,Pain and discomfort NEC,General system disorders NEC,Genrl,N
205,3,Pain,Pain and discomfort NEC,General system disorders NEC,Genrl,N
206,1,Blood alkaline phosphatase increased,Tissue enzyme analyses NEC,Enzyme investigations NEC,Inv,N
206,2,Carbohydrate antigen 15-3 increased,Cell marker analyses,Cytogenetic investigations and genetic analyses,Inv,N
206,3,Malignant neoplasm progression,Neoplasms malignant site unspecified NEC,Miscellaneous and site unspecified neoplasms malignant and unspecified,Neopl,N
207,1,Hyperglycaemia,Hyperglycaemic conditions NEC,Glucose metabolism disorders (incl diabetes mellitus),Metab,N
208,1,Malignant neoplasm progression,Neoplasms malignant site unspecified NEC,Miscellaneous and site unspecified neoplasms malignant and unspecified,Neopl,N
209,1,Cardiac failure acute,Heart failures NEC,Heart failures,Card,N
209,2,Glomerular filtration rate abnormal,Renal function analyses,Renal and urinary tract investigations and urinalyses,Inv,N
209,3,Haemoglobin decreased,Red blood cell analyses,Haematology investigations (incl blood groups),Inv,N
209,4,Malignant neoplasm progression,Neoplasms malignant site unspecified NEC,Miscellaneous and site unspecified neoplasms malignant and unspecified,Neopl,N
209,5,Metastases to lung,Metastases to specified sites,Metastases,Neopl,N
209,6,Metastases to lymph nodes,Metastases to specified sites,Metastases,Neopl,N
209,7,Neutrophil count increased,White blood cell analyses,Haematology investigations (incl blood groups),Inv,N
209,8,Peripheral ischaemia,"Peripheral vasoconstriction, necrosis and vascular insufficiency","Arteriosclerosis, stenosis, vascular insufficiency and necrosis",Vasc,N
209,9,Platelet count increased,Platelet analyses,Haematology investigations (incl blood groups),Inv,N
209,10,Pneumonia,Lower respiratory tract and lung infections,Infections - pathogen unspecified,Infec,N
209,11,Thrombosis,Non-site specific embolism and thrombosis,Embolism and thrombosis,Vasc,N
209,12,White blood cell count increased,White blood cell analyses,Haematology investigations (incl blood groups),Inv,N
210,1,Alanine aminotransferase decreased,Hepatobiliary function diagnostic procedures,Hepatobiliary investigations,Inv,N
210,2,Blood alkaline phosphatase abnormal,Tissue enzyme analyses NEC,Enzyme investigations NEC,Inv,N
211,1,Bone pain,Bone related signs and symptoms,Bone disorders (excl congenital and fractures),Musc,N
211,2,Breast cancer recurrent,Breast and nipple neoplasms malignant,Breast neoplasms malignant and unspecified (incl nipple),Neopl,N
211,3,Myelosuppression,Marrow depression and hypoplastic anaemias,Anaemias nonhaemolytic and marrow depression,Blood,N
211,4,Off label use,Off label uses,Off label uses and intentional product misuses/use issues,Inj&P,N
212,1,Breast cancer recurrent,Breast and nipple neoplasms malignant,Breast neoplasms malignant and unspecified (incl nipple),Neopl,N
212,2,Malignant neoplasm progression,Neoplasms malignant site unspecified NEC,Miscellaneous and site unspecified neoplasms malignant and unspecified,Neopl,N
213,1,Carbohydrate antigen 15-3 increased,Cell marker analyses,Cytogenetic investigations and genetic analyses,Inv,N
213,2,Liver disorder,Hepatic and hepatobiliary disorders NEC,Hepatic and hepatobiliary disorders,Hepat,N
213,3,Metastases to bone,Metastases to specified sites,Metastases,Neopl,N
214,1,Alanine aminotransferase abnormal,Hepatobiliary function diagnostic procedures,Hepatobiliary investigations,Inv,N
214,2,Arthralgia,Joint related signs and symptoms,Joint disorders,Musc,N
214,3,Blood albumin abnormal,Protein analyses NEC,Protein and chemistry analyses NEC,Inv,N
214,4,Blood alkaline phosphatase abnormal,Tissue enzyme analyses NEC,Enzyme investigations NEC,Inv,N
214,5,Blood bilirubin abnormal,Hepatobiliary function diagnostic procedures,Hepatobiliary investigations,Inv,N
214,6,Blood calcium abnormal,Mineral and electrolyte analyses,"Water, electrolyte and mineral investigations",Inv,N
214,7,Blood creatinine abnormal,Renal function analyses,Renal and urinary tract investigations and urinalyses,Inv,N
214,8,Chest pain,Pain and discomfort NEC,General system disorders NEC,Genrl,N
214,9,Chest wall mass,Musculoskeletal and connective tissue conditions NEC,Musculoskeletal and connective tissue disorders NEC,Musc,N
214,10,Dyspnoea,Breathing abnormalities,Respiratory disorders NEC,Resp,N
214,11,Glomerular filtration rate increased,Renal function analyses,Renal and urinary tract investigations and urinalyses,Inv,N
214,12,Haemoglobin abnormal,Red blood cell analyses,Haematology investigations (incl blood groups),Inv,N
214,13,Lymphadenopathy,Lymphatic system disorders NEC,"Spleen, lymphatic and reticuloendothelial system disorders",Blood,N
214,14,Musculoskeletal toxicity,Musculoskeletal and connective tissue conditions NEC,Musculoskeletal and connective tissue disorders NEC,Musc,N
214,15,Neutrophil count abnormal,White blood cell analyses,Haematology investigations (incl blood groups),Inv,N
214,16,Pain,Pain and discomfort NEC,General system disorders NEC,Genrl,N
214,17,Platelet count decreased,Platelet analyses,Haematology investigations (incl blood groups),Inv,N
214,18,Pulmonary mass,Respiratory tract disorders NEC,Respiratory disorders NEC,Resp,N
214,19,Scan abnormal,Imaging procedures NEC,"Investigations, imaging and histopathology procedures NEC",Inv,N
214,20,Toxicity to various agents,Poisoning and toxicity,"Exposures, chemical injuries and poisoning",Inj&P,N
214,21,White blood cell count abnormal,White blood cell analyses,Haematology investigations (incl blood groups),Inv,N
215,1,Alanine aminotransferase decreased,Hepatobiliary function diagnostic procedures,Hepatobiliary investigations,Inv,N
215,2,Blood alkaline phosphatase abnormal,Tissue enzyme analyses NEC,Enzyme investigations NEC,Inv,N
216,1,Bone pain,Bone related signs and symptoms,Bone disorders (excl congenital and fractures),Musc,N
216,2,Breast cancer recurrent,Breast and nipple neoplasms malignant,Breast neoplasms malignant and unspecified (incl nipple),Neopl,N
216,3,Myelosuppression,Marrow depression and hypoplastic anaemias,Anaemias nonhaemolytic and marrow depression,Blood,N
216,4,Off label use,Off label uses,Off label uses and intentional product misuses/use issues,Inj&P,N
217,1,Breast cancer metastatic,Breast and nipple neoplasms malignant,Breast neoplasms malignant and unspecified (incl nipple),Neopl,N
217,2,Haemoglobin decreased,Red blood cell analyses,Haematology investigations (incl blood groups),Inv,N
218,1,Drug ineffective,Therapeutic and nontherapeutic responses,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
218,2,Malignant neoplasm progression,Neoplasms malignant site unspecified NEC,Miscellaneous and site unspecified neoplasms malignant and unspecified,Neopl,N
219,1,Metastases to liver,Metastases to specified sites,Metastases,Neopl,N
220,1,Lichen sclerosus,Papulosquamous conditions,Epidermal and dermal conditions,Skin,N
221,1,Lichen sclerosus,Papulosquamous conditions,Epidermal and dermal conditions,Skin,N
222,1,Lichen sclerosus,Papulosquamous conditions,Epidermal and dermal conditions,Skin,N
223,1,Lichen sclerosus,Papulosquamous conditions,Epidermal and dermal conditions,Skin,N
224,1,Lichen sclerosus,Papulosquamous conditions,Epidermal and dermal conditions,Skin,N
225,1,Lichen sclerosus,Papulosquamous conditions,Epidermal and dermal conditions,Skin,N
226,1,Chest discomfort,Pain and discomfort NEC,General system disorders NEC,Genrl,N
226,2,Cough,Coughing and associated symptoms,Respiratory disorders NEC,Resp,N
226,3,Dizziness,Neurological signs and symptoms NEC,Neurological disorders NEC,Nerv,N
226,4,Dyspnoea,Breathing abnormalities,Respiratory disorders NEC,Resp,N
226,5,Headache,Headaches NEC,Headaches,Nerv,N
226,6,Nausea,Nausea and vomiting symptoms,Gastrointestinal signs and symptoms,Gastr,N
226,7,Vomiting,Nausea and vomiting symptoms,Gastrointestinal signs and symptoms,Gastr,N
227,1,Lichen sclerosus,Papulosquamous conditions,Epidermal and dermal conditions,Skin,N
228,1,Death,Death and sudden death,Fatal outcomes,Genrl,Y
228,2,Hypothyroidism,Thyroid hypofunction disorders,Thyroid gland disorders,Endo,N
229,1,Injection site pain,Injection site reactions,Administration site reactions,Genrl,N
230,1,Hyperkeratosis,Hyperkeratoses,Cornification and dystrophic skin disorders,Skin,N
230,2,Lichen sclerosus,Papulosquamous conditions,Epidermal and dermal conditions,Skin,N
230,3,Lichenoid keratosis,Hyperkeratoses,Cornification and dystrophic skin disorders,Skin,N
230,4,Rash,"Rashes, eruptions and exanthems NEC",Epidermal and dermal conditions,Skin,N
230,5,Skin hypopigmentation,Hypopigmentation disorders,Pigmentation disorders,Skin,N
230,6,Skin plaque,Dermal and epidermal conditions NEC,Epidermal and dermal conditions,Skin,N
231,1,Lichen sclerosus,Papulosquamous conditions,Epidermal and dermal conditions,Skin,N
232,1,Hyperglycaemia,Hyperglycaemic conditions NEC,Glucose metabolism disorders (incl diabetes mellitus),Metab,N
233,1,Lichen sclerosus,Papulosquamous conditions,Epidermal and dermal conditions,Skin,N
234,1,Lichen sclerosus,Papulosquamous conditions,Epidermal and dermal conditions,Skin,N
235,1,Rash,"Rashes, eruptions and exanthems NEC",Epidermal and dermal conditions,Skin,N
236,1,Sinus tachycardia,Supraventricular arrhythmias,Cardiac arrhythmias,Card,N
237,1,Fatigue,Asthenic conditions,General system disorders NEC,Genrl,N
238,1,Rash pruritic,"Rashes, eruptions and exanthems NEC",Epidermal and dermal conditions,Skin,N
239,1,Hyperglycaemia,Hyperglycaemic conditions NEC,Glucose metabolism disorders (incl diabetes mellitus),Metab,N
240,1,Lichen sclerosus,Papulosquamous conditions,Epidermal and dermal conditions,Skin,N
241,1,Fatigue,Asthenic conditions,General system disorders NEC,Genrl,N
241,2,Nausea,Nausea and vomiting symptoms,Gastrointestinal signs and symptoms,Gastr,N
242,1,Gait disturbance,Gait disturbances,General system disorders NEC,Genrl,N
242,2,Injection site pain,Injection site reactions,Administration site reactions,Genrl,N
243,1,Muscular weakness,Muscle weakness conditions,Muscle disorders,Musc,N
243,2,Sciatica,Lumbar spinal cord and nerve root disorders,Spinal cord and nerve root disorders,Nerv,N
244,1,Arthralgia,Joint related signs and symptoms,Joint disorders,Musc,N
245,1,Gene mutation identification test positive,Gene analyses,Cytogenetic investigations and genetic analyses,Inv,N
245,2,Malignant neoplasm progression,Neoplasms malignant site unspecified NEC,Miscellaneous and site unspecified neoplasms malignant and unspecified,Neopl,N
246,1,Buttock injury,Site specific injuries NEC,Injuries NEC,Inj&P,N
